{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:19:36Z","timestamp":1795040376027,"version":"4.10.2"},"reference-count":126,"publisher":"Bentham Science Publishers Ltd.","issue":"21","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The primary feature of Parkinson's disease (PD), a progressive neurodegenerative disease\nthat results in both motor and non-motor dysfunctions, is the degeneration of dopaminergic neurons\nin the substantia nigra. In recent years, indole-based compounds have emerged as promising candidates\nfor developing novel treatments for Parkinson's disease due to their diverse pharmacological\nproperties. Among the significant pathogenic targets against which indole derivatives exhibit potent\nactivity are monoamine oxidase (MAO), NMDA receptors, oxidative stress, and neuroinflammation.\nThis review provides an in-depth analysis of synthetic indole derivatives as potential therapeutic\nagents for Parkinson\u2019s disease. We explore how these compounds may reduce the pathology associated\nwith Parkinson's disease, identify molecular targets, and analyze the relationships between their\nstructure and activity. We also discuss recent advances in computational and medicinal chemistry\nthat aim to enhance indole structures. Potential challenges and upcoming prospects for the therapeutic\napplication of indole-based therapies are also considered in the review. The ultimate objective of\nthis study is to elucidate the potential applications of synthetic indole derivatives in the development\nof innovative therapies for Parkinson's disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113895575400809251007055201","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:00:20Z","timestamp":1761192020000},"page":"1643-1656","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring Indole-Based Molecules as Novel Therapeutics for Parkinson\u2019s Disease: A Comprehensive Review"],"prefix":"10.2174","volume":"25","author":[{"given":"Ritam","family":"Mondal","sequence":"first","affiliation":[{"name":"Department of Pharmacy, School of Medical &amp; Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2444-1500","authenticated-orcid":true,"given":"Deepika","family":"Paliwal","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical &amp; Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Thakur","sequence":"additional","affiliation":[{"name":"Adarsh Vijendra Institute of Pharmaceutical Sciences, Shobhit University, Gangoh, Saharanpur, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical &amp; Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Kaushik","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical &amp; Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/bmj.292.6519.534","volume":"292","author":"Mutch W.J.","year":"1986","unstructured":"Mutch W.J.; Dingwall-Fordyce I.; Downie A.W.; Paterson J.G.; Roy S.K.; Parkinson\u2019s disease in a Scottish city. BMJ  1986,292(6519),534-536","journal-title":"BMJ"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.expneurol.2004.08.021","volume":"191","author":"Betarbet R.","year":"2005","unstructured":"Betarbet R.; Sherer T.B.; Greenamyre J.T.; Ubiquitin\u2013proteasome system and Parkinson\u2019s diseases. Exp Neurol  (Suppl. 1)2005,191,S17-S27","journal-title":"Exp Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/mds.21065","volume":"21","author":"Braak H.","year":"2006","unstructured":"Braak H.; Bohl J.R.; M\u00fcller C.M.; R\u00fcb U.; de Vos R.A.I.; Del Tredici K.; Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson\u2019s disease reconsidered. Mov Disord  2006,21(12),2042-2051","journal-title":"Mov Disord"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/01.wco.0000186841.43505.e6","volume":"18","author":"Cookson M.R.","year":"2005","unstructured":"Cookson M.R.; Xiromerisiou G.; Singleton A.; How genetics research in Parkinson\u2019s disease is enhancing understanding of the common idiopathic forms of the disease. Curr Opin Neurol  2005,18(6),706-711","journal-title":"Curr Opin Neurol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0140-6736(05)17830-1","volume":"365","author":"Gilks W.P.","year":"2005","unstructured":"Gilks W.P.; Abou-Sleiman P.M.; Gandhi S.; Jain S.; Singleton A.; Lees A.J.; Shaw K.; Bhatia K.P.; Bonifati V.; Quinn N.P.; Lynch J.; Healy D.G.; Holton J.L.; Revesz T.; Wood N.W.; A common LRRK2 mutation in idiopathic Parkinson\u2019s disease. Lancet  2005,365(9457),415-416","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nm1001-1144","volume":"7","author":"Chung K.K.K.","year":"2001","unstructured":"Chung K.K.K.; Zhang Y.; Lim K.L.; Tanaka Y.; Huang H.; Gao J.; Ross C.A.; Dawson V.L.; Dawson T.M.; Parkin ubiquitinates the \u03b1-synuclein\u2013interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med  2001,7(10),1144-1150","journal-title":"Nat Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1002\/ana.10487","volume":"53","author":"Warner T.T.","year":"2003","unstructured":"Warner T.T.; Schapira A.H.V.; Genetic and environmental factors in the cause of Parkinson\u2019s disease. Ann Neurol  2003,53(S3),S16-S25","journal-title":"Ann Neurol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3390\/neurolint16030037","volume":"16","author":"Bej E.","year":"2024","unstructured":"Bej E.; Cesare P.; Volpe A.R.; d\u2019Angelo M.; Castelli V.; Oxidative stress and neurodegeneration: Insights and therapeutic strategies for parkinson\u2019s disease. Neurol Int  2024,16(3),502-517","journal-title":"Neurol Int"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.3390\/ijms24032642","volume":"24","author":"Chiu Y.J.","year":"2023","unstructured":"Chiu Y.J.; Lin C.H.; Lin C.Y.; Yang P.N.; Lo Y.S.; Chen Y.C.; Chen C.M.; Wu Y.R.; Yao C.F.; Chang K.H.; Lee-Chen G.J.; Investigating therapeutic effects of indole derivatives targeting inflammation and oxidative stress in neurotoxin-induced cell and mouse models of parkinson\u2019s disease. Int J Mol Sci  2023,24(3),2642","journal-title":"Int J Mol Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1056\/NEJM199601113340202","volume":"334","author":"Bennett D.A.","year":"1996","unstructured":"Bennett D.A.; Beckett L.A.; Murray A.M.; Shannon K.M.; Goetz C.G.; Pilgrim D.M.; Evans D.A.; Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med  1996,334(2),71-76","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","volume":"284","author":"Group P.S.","year":"2000","unstructured":"Group P.S.; Group P.S.; Pramipexole vs. levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA  2000,284(15),1931-1938","journal-title":"JAMA"},{"key":"ref=12","author":"Hughes A.J.","year":"1992","unstructured":"Hughes A.J.; Daniel S.E.; Kilford L.; Lees A.J.; Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry  1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1056\/NEJM197201062860102","volume":"286","author":"Papavasiliou P.S.","year":"1972","unstructured":"Papavasiliou P.S.; Cotzias G.C.; D\u00fcby S.E.; Steck A.J.; Fehling C.; Bell M.A.; Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor. N Engl J Med  1972,286(1),8-14","journal-title":"N Engl J Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ana.410160303","volume":"16","author":"Rajput A.H.","year":"1984","unstructured":"Rajput A.H.; Offord K.P.; Beard C.M.; Kurland L.T.; Epidemiology of parkinsonism: Incidence, classification, and mortality. Ann Neurol  1984,16(3),278-282","journal-title":"Ann Neurol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1001\/jama.290.4.511","volume":"290","author":"Sejvar J.J.","year":"2003","unstructured":"Sejvar J.J.; Haddad M.B.; Tierney B.C.; Campbell G.L.; Marfin A.A.; Van Gerpen J.A.; Fleischauer A.; Leis A.A.; Stokic D.S.; Petersen L.R.; Neurologic manifestations and outcome of West Nile virus infection. JAMA  2003,290(4),511-515","journal-title":"JAMA"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"Aarsland D.","year":"2021","unstructured":"Aarsland D.; Batzu L.; Halliday G.M.; Geurtsen G.J.; Ballard C.; Ray Chaudhuri K.; Weintraub D.; Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers  2021,7(1),47","journal-title":"Nat Rev Dis Primers"},{"key":"ref=17","author":"Dorsey R.","year":"2020","unstructured":"Dorsey R.; Sherer T.; Okun M.S.; Bloem B.R.;  Ending Parkinson\u2019s Disease: A Prescription for Action  2020","journal-title":"Ending Parkinson\u2019s Disease: A Prescription for Action"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"a033118","DOI":"10.1101\/cshperspect.a033118","volume":"10","author":"Erkkinen M.G.","year":"2018","unstructured":"Erkkinen M.G.; Kim M.O.; Geschwind M.D.; Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol  2018,10(4),a033118","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2119\/2007-00100.Irvine","volume":"14","author":"Irvine G.B.","year":"2008","unstructured":"Irvine G.B.; El-Agnaf O.M.; Shankar G.M.; Walsh D.M.; Protein aggregation in the brain: the molecular basis for Alzheimer\u2019s and Parkinson\u2019s diseases. Mol Med  2008,14(7-8),451-464","journal-title":"Mol Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0072-9752(07)83006-5","volume":"83","author":"Kasten M.","year":"2007","unstructured":"Kasten M.; Chade A.; Tanner C.M.; Epidemiology of Parkinson\u2019s disease. Handb Clin Neurol  2007,83,129-151","journal-title":"Handb Clin Neurol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"101301","DOI":"10.1016\/j.rechem.2023.101301","volume":"7","author":"Sahu R.","year":"2024","unstructured":"Sahu R.; Shah K.; Malviya R.; Paliwal D.; Sagar S.; Singh S.; Prajapati B.G.; Recent advancement in pyrrolidine moiety for the management of cancer: A review. Results Chem  2024,7,101301","journal-title":"Results Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e202500130","DOI":"10.1002\/slct.202500130","volume":"10","author":"Thakur A.","year":"2025","unstructured":"Thakur A.; Singh R.; Mehta V.; Paliwal D.; Role of pyrazole moiety in the treatment of Alzheimer\u2019s disease: A comprehensive review of various synthetic routes and probable mechanisms of action. ChemistrySelect  2025,10(13),e202500130","journal-title":"ChemistrySelect"},{"key":"ref=23","author":"Dodd C.A.","year":"2009","unstructured":"Dodd C.A.;  Synthetic and natural environmental compounds as potential facilitators of mptp-induced parkinsonism  2009","journal-title":"Synthetic and natural environmental compounds as potential facilitators of mptp-induced parkinsonism"},{"key":"ref=24","author":"Gartner C.E.","year":"2006","unstructured":"Gartner C.E.;  Environmental Risk Factors for Parkinson\u2019s Disease  2006","journal-title":"Environmental Risk Factors for Parkinson\u2019s Disease"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev-pharmtox-011613-135937","volume":"54","author":"Goldman S.M.","year":"2014","unstructured":"Goldman S.M.; Environmental toxins and Parkinson\u2019s disease. Annu Rev Pharmacol Toxicol  2014,54(1),141-164","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"10808","DOI":"10.3390\/ijms231810808","volume":"23","author":"Huang M.","year":"2022","unstructured":"Huang M.; Bargues-Carot A.; Riaz Z.; Wickham H.; Zenitsky G.; Jin H.; Anantharam V.; Kanthasamy A.; Kanthasamy A.G.; Impact of environmental risk factors on mitochondrial dysfunction, neuroinflammation, protein misfolding, and oxidative stress in the etiopathogenesis of parkinson\u2019s disease. Int J Mol Sci  2022,23(18),10808","journal-title":"Int J Mol Sci"},{"key":"ref=27","first-page":"37","author":"Nath B.D.","year":"2021","unstructured":"Nath B.D.; Debnath D.; Pervin R.; Hossain M.A.; Role of Environmental Toxicants and Inflammation in Parkinson\u2019s Disease. Antioxidants and functional foods for neurodegenerative disorders  2021,37-69","journal-title":"Antioxidants and functional foods for neurodegenerative disorders"},{"key":"ref=28","author":"Phom L.","year":"2018","unstructured":"Phom L.; Understanding Neurodegeneration and Rescuing Pathology Associated with Parkinsons Disease in Drosophila Model. Thesis  2018","journal-title":"Thesis"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-96-4154-3_13","author":"Mondal R.","year":"2025","unstructured":"Mondal R.; Paliwal D.; Thakur A.; Sahu R.; Budha R.R.; Protein Binding Prediction by Computational Methods. Applications of Computational Tools in Drug Design and Development  2025","journal-title":"Applications of Computational Tools in Drug Design and Development"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/bmb\/ldl018","volume":"79-80","author":"Dick F.D.","year":"2006","unstructured":"Dick F.D.; Parkinson\u2019s disease and pesticide exposures. Br Med Bull  2006,79-80(1),219-231","journal-title":"Br Med Bull"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.2174\/0118715249333381241012073557","author":"Sharma S.","year":"2024","unstructured":"Sharma S.; Rahate K.; Kumar R.; Novel emerging targets identification in reducing risk of Alzheimer's disease. Cent Nerv Syst Agents Med Chem  2024","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jnnp.2006.098327","volume":"78","author":"Grosset D.","year":"2006","unstructured":"Grosset D.; Taurah L.; Burn D.J.; MacMahon D.; Forbes A.; Turner K.; Bowron A.; Walker R.; Findley L.; Foster O.; Patel K.; Clough C.; Castleton B.; Smith S.; Carey G.; Murphy T.; Hill J.; Brechany U.; McGee P.; Reading S.; Brand G.; Kelly L.; Breen K.; Ford S.; Baker M.; Williams A.; Hearne J.; Qizilbash N.; Chaudhuri K.R.; A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson\u2019s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry  2006,78(5),465-469","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/jnnp.2006.109454","volume":"78","author":"Hagell P.","year":"2006","unstructured":"Hagell P.; Self-reported health in people with Parkinson\u2019s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry  2006,78(5),442","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1136\/bmj.310.6995.1668","volume":"310","author":"Hawkes C.M.","year":"1995","unstructured":"Hawkes C.M.; Diagnosis and treatment of Parkinson\u2019s disease. BMJ  1995,310(6995),1668","journal-title":"BMJ"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/brain\/awf080","volume":"125","author":"Hughes A.J.","year":"2002","unstructured":"Hughes A.J.; Daniel S.E.; Ben-Shlomo Y.; Lees A.J.; The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain  2002,125(4),861-870","journal-title":"Brain"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1002\/mds.10573","volume":"18","author":"Poewe W.","year":"2003","unstructured":"Poewe W.; Scherfler C.; Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord  2003,18(S7),S16-S21","journal-title":"Mov Disord"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1474-4422(07)70327-7","volume":"7","author":"Schapira A.H.V.","year":"2008","unstructured":"Schapira A.H.V.; Mitochondria in the aetiology and pathogenesis of Parkinson\u2019s disease. Lancet Neurol  2008,7(1),97-109","journal-title":"Lancet Neurol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1001\/jama.291.3.358","volume":"291","author":"Schapira A.H.V.","year":"2004","unstructured":"Schapira A.H.V.; Olanow C.W.; Neuroprotection in Parkinson disease: Mysteries, myths, and misconceptions. JAMA  2004,291(3),358-364","journal-title":"JAMA"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1002\/mds.21685","volume":"22","author":"Schneider S.A.","year":"2007","unstructured":"Schneider S.A.; Edwards M.J.; Mir P.; Cordivari C.; Hooker J.; Dickson J.; Quinn N.; Bhatia K.P.; Patients with adult\u2010onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord  2007,22(15),2210-2215","journal-title":"Mov Disord"},{"key":"ref=40","first-page":"1539","volume":"85","author":"Sahu R.","year":"2023","unstructured":"Sahu R.; Shah K.; Misbah A.; Paliwal D.; Sharma N.; Rani T.; Recent advancement of benzofuran in treatment of Alzheimer\u2019s disease. Indian J Pharm Sci  2023,85,1539-1550","journal-title":"Indian J Pharm Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","volume":"59","author":"Group P.S.","year":"2002","unstructured":"Group P.S.; A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol  2002,59(12),1937-1943","journal-title":"Arch Neurol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1136\/bmj.311.7020.1602","volume":"311","author":"Lees A.J.","year":"1995","unstructured":"Lees A.J.; Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson\u2019s disease. BMJ  1995,311(7020),1602-1607","journal-title":"BMJ"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.parkreldis.2006.02.004","volume":"12","author":"Imamura A.","year":"2006","unstructured":"Imamura A.; Uitti R.J.; Wszolek Z.K.; Dopamine agonist therapy for Parkinson disease and pathological gambling. Parkinsonism Relat Disord  2006,12(8),506-508","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","volume":"123","author":"Schrag A.","year":"2000","unstructured":"Schrag A.; Quinn N.; Dyskinesias and motor fluctuations in Parkinson\u2019s disease. Brain  2000,123(11),2297-2305","journal-title":"Brain"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00002826-200305000-00001","volume":"26","author":"M\u00fcller T.","year":"2003","unstructured":"M\u00fcller T.; Fritze J.; Fibrosis associated with dopamine agonist therapy in Parkinson\u2019s disease. Clin Neuropharmacol  2003,26(3),109-111","journal-title":"Clin Neuropharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/bmj.38184.606169.AE","volume":"329","author":"Ives N.J.","year":"2004","unstructured":"Ives N.J.; Stowe R.L.; Marro J.; Counsell C.; Macleod A.; Clarke C.E.; Gray R.; Wheatley K.; Monoamine oxidase type B inhibitors in early Parkinson\u2019s disease: Meta-analysis of 17 randomised trials involving 3525 patients. BMJ  2004,329(7466),593","journal-title":"BMJ"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archneur.56.5.529","volume":"56","author":"Fahn S.","year":"1999","unstructured":"Fahn S.; Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs. Later L-DOPA. Arch Neurol  1999,56(5),529-535","journal-title":"Arch Neurol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1212\/01.wnl.0000218206.20920.4d","volume":"66","author":"Voon V.","year":"2006","unstructured":"Voon V.; Hassan K.; Zurowski M.; Duff-Canning S.; de Souza M.; Fox S.; Lang A.E.; Miyasaki J.; Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology  2006,66(11),1750-1752","journal-title":"Neurology"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/jnnp.44.11.1020","volume":"44","author":"Lees A.J.","year":"1981","unstructured":"Lees A.J.; Stern G.M.; Sustained Bromocriptine Therapy in Previously Untreated Patients with Parkinson{\\textquoteright}s Disease. J Neurol Neurosurg Psychiatry  1981,44,1020-1023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.2174\/1570180820666230427151812","volume":"21","author":"Paliwal D.","year":"2024","unstructured":"Paliwal D.; Rao Gudhanti S.N.K.; Yadav D.; Raj P.; Insight into quantum computing and deep learning approach for drug design. Lett Drug Des Discov  2024,21,1632-1651","journal-title":"Lett Drug Des Discov"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4018\/979-8-3693-2238-3.ch005","author":"Rahate K.P.","year":"2024","unstructured":"Rahate K.P.; Mondal R.;  Applications of AI in Drug Discovery: Its Challenges, Opportunities, and StrategiesApproaches to Human-Centered AI Healthc  2024,86-120","journal-title":"Applications of AI in Drug Discovery: Its Challenges, Opportunities, and StrategiesApproaches to Human-Centered AI Healthc"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.2174\/0115680266358563250331175140","volume":"25","author":"Mondal R.","year":"2025","unstructured":"Mondal R.; Paliwal D.; Thakur A.; Kaushik N.; An insight into the recent advancement in anti-alzheimer\u2019s potential of indole derivatives and their SAR Study. Curr Top Med Chem  2025,25(24),2848-2863","journal-title":"Curr Top Med Chem"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"8093","DOI":"10.1128\/AEM.02787-15","volume":"81","author":"Darkoh C.","year":"2015","unstructured":"Darkoh C.; Chappell C.; Gonzales C.; Okhuysen P.; A rapid and specific method for the detection of indole in complex biological samples. Appl Environ Microbiol  2015,81(23),8093-8097","journal-title":"Appl Environ Microbiol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.chemphys.2004.07.004","volume":"304","author":"Mourik T.","year":"2004","unstructured":"Mourik T.; Theoretical study of indole: Protonation, indolyl radical, tautomers of indole, and its interaction with water. Chem Phys  2004,304(3),317-319","journal-title":"Chem Phys"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"9088","DOI":"10.1021\/jo0614339","volume":"71","author":"Lakhdar S.","year":"2006","unstructured":"Lakhdar S.; Westermaier M.; Terrier F.; Goumont R.; Boubaker T.; Ofial A.R.; Mayr H.; Nucleophilic reactivities of indoles. J Org Chem  2006,71(24),9088-9095","journal-title":"J Org Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1021\/j100372a022","volume":"94","author":"Eftink M.R.","year":"1990","unstructured":"Eftink M.R.; Selvidge L.A.; Callis P.R.; Rehms A.A.; Photophysics of indole derivatives: Experimental resolution of La and Lb transitions and comparison with theory. J Phys Chem  1990,94(9),3469-3479","journal-title":"J Phys Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bbi.2019.12.005","volume":"84","author":"Casaril A.M.","year":"2020","unstructured":"Casaril A.M.; Domingues M.; Bampi S.R.; Louren\u00e7o D.A.; Smaniotto T.\u00c2.; Segatto N.; Vieira B.; Seixas F.K.; Collares T.; Lenard\u00e3o E.J.; Savegnago L.; The antioxidant and immunomodulatory compound 3-[(4-chlorophenyl)selanyl]-1-methyl-1H-indole attenuates depression-like behavior and cognitive impairment developed in a mouse model of breast tumor. Brain Behav Immun  2020,84,229-241","journal-title":"Brain Behav Immun"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.brainresbull.2020.05.008","volume":"161","author":"Bampi S.R.","year":"2020","unstructured":"Bampi S.R.; Casaril A.M.; Fronza M.G.; Domingues M.; Vieira B.; Begnini K.R.; Seixas F.K.; Collares T.V.; Lenard\u00e3o E.J.; Savegnago L.; The selenocompound 1-methyl-3-(phenylselanyl)-1H-indole attenuates depression-like behavior, oxidative stress, and neuroinflammation in streptozotocin-treated mice. Brain Res Bull  2020,161,158-165","journal-title":"Brain Res Bull"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/0115680266360926250509040743","author":"Mondal R.","year":"2025","unstructured":"Mondal R.; Rahate K.; Chaudhary S.; Targeting cell signalling pathways with new small molecules in inflammation and cancer. Curr Top Med Chem  2025,25","journal-title":"Curr Top Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40203-025-00364-y","volume":"13","author":"Paliwal D.","year":"2025","unstructured":"Paliwal D.; Mondal R.; Thakur A.; 2D-QSAR and molecular docking based virtual screening and molecular dynamic simulation of the indole based herbal molecules for the discovery of potent molecules in the treatment of Alzheimer\u2019s disease. In Silico Pharmacol  2025,13(2),81","journal-title":"In Silico Pharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","DOI":"10.22376\/ijpbs\/lpr.2021.11.4.P19-P24","author":"Sakinala P.","year":"2021","unstructured":"Sakinala P.; Rahaman K.S.; Mounika V.; Sathvika K.; A comprehensive knowledge on review of indole derivatives. Int J Life Sci Pharma Res  2021","journal-title":"Int J Life Sci Pharma Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41598-017-01964-1","volume":"7","author":"Samaraweera L.","year":"2017","unstructured":"Samaraweera L.; Adomako A.; Rodriguez-Gabin A.; McDaid H.M.; A novel indication for panobinostat as a senolytic drug in NSCLC and HNSCC. Sci Rep  2017,7(1),1900","journal-title":"Sci Rep"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","volume":"21","author":"Laubach J.P.","year":"2015","unstructured":"Laubach J.P.; Moreau P.; San-Miguel J.F.; Richardson P.G.; Panobinostat for the treatment of multiple myeloma. Clin Cancer Res  2015,21(21),4767-4773","journal-title":"Clin Cancer Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","volume":"75","author":"Garnock-Jones K.P.","year":"2015","unstructured":"Garnock-Jones K.P.; Panobinostat: First global approval. Drugs  2015,75(6),695-704","journal-title":"Drugs"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/S0960-894X(99)00248-6","volume":"9","author":"Tamiz A.P.","year":"1999","unstructured":"Tamiz A.P.; Whittemore E.R.; Woodward R.M.; Upasani R.B.; Keana J.F.W.; Structure-Activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-methyl-D-aspartate (NMDA) receptors. Bioorg Med Chem Lett  1999,9(11),1619-1624","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1517\/13543784.2012.646081","volume":"21","author":"Yutkin V.","year":"2012","unstructured":"Yutkin V.; Chin J.; Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer. Expert Opin Investig Drugs  2012,21(2),251-260","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ucl.2019.09.009","volume":"47","author":"Arends T.J.H.","year":"2020","unstructured":"Arends T.J.H.; Alfred Witjes J.; Apaziquone for nonmuscle invasive bladder cancer. Urol Clin North Am  2020,47(1),73-82","journal-title":"Urol Clin North Am"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003495-199346050-00009","volume":"46","author":"Lee C.R.","year":"1993","unstructured":"Lee C.R.; Plosker G.L.; McTavish D.; Tropisetron. Drugs  1993,46(5),925-943","journal-title":"Drugs"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/00003495-199200433-00005","volume":"43","author":"de Bruijn K.M.","year":"1992","unstructured":"de Bruijn K.M.; Tropisetron. Drugs  1992,43,11-22","journal-title":"Drugs"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0014-2999(02)02647-X","volume":"456","author":"Metzger R.R.","year":"2002","unstructured":"Metzger R.R.; Brown J.M.; Sandoval V.; Rau K.S.; Elwan M.A.; Miller G.W.; Hanson G.R.; Fleckenstein A.E.; Inhibitory effect of reserpine on dopamine transporter function. Eur J Pharmacol  2002,456(1-3),39-43","journal-title":"Eur J Pharmacol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.bbrc.2015.04.145","volume":"462","author":"Lee K.I.","year":"2015","unstructured":"Lee K.I.; Kim M.J.; Koh H.; Lee J.I.; Namkoong S.; Oh W.K.; Park J.; The anti-hypertensive drug reserpine induces neuronal cell death through inhibition of autophagic flux. Biochem Biophys Res Commun  2015,462(4),402-408","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/HJH.0b013e328340a08e","volume":"29","author":"Neglia D.","year":"2011","unstructured":"Neglia D.; Fommei E.; Carver A.V.; Mancini M.; Ghione S.; Lombardi M.; Pisani P.; Parker H.; D\u2019Amati G.; Donato L.; Treatment of hypertension with perindopril plus indapamide leads to reverse coronary microvascular remodelling and improved blood flow. J Hypertens  2011,29,364-372","journal-title":"J Hypertens"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/0002-8703(82)90125-9","volume":"104","author":"Aellig W.H.","year":"1982","unstructured":"Aellig W.H.; Clinical pharmacology of pindolol. Am Heart J  1982,104(2),346-356","journal-title":"Am Heart J"},{"key":"ref=74","author":"Artigas F.","year":"2006","unstructured":"Artigas F.; Adell A.; Celada P.; Pindolol augmentation of antidepressant response. Current Drug Targets  Feb 1;7(2):139-47.2006","journal-title":"Current Drug Targets"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/jps.2600740706","volume":"74","author":"Morin D.","year":"1985","unstructured":"Morin D.; Zini R.; Ledewyn S.; Colonna J.P.; Czajka M.; Tillement J.P.; Binedaline binding to plasma proteins and red blood cells in humans. J Pharm Sci  1985,74(7),727-730","journal-title":"J Pharm Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/S0022-3565(25)23253-0","volume":"249","author":"Morin D.","year":"1989","unstructured":"Morin D.; Zini R.; Urien S.; Tillement J.P.; Pharmacological profile of binedaline, a new antidepressant drug. J Pharmacol Exp Ther  1989,249(1),288-296","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/BF00427453","volume":"84","author":"Blier P.","year":"1984","unstructured":"Blier P.; de Montigny C.; Tardif D.; Effects of the two antidepressant drugs mianserin and indalpine on the serotonergic system: Single-cell studies in the rat. Psychopharmacology (Berl)  1984,84(2),242-249","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/0028-3908(80)90104-5","volume":"19","author":"Uzan A.","year":"1980","unstructured":"Uzan A.; Kabouche M.; Rataud J.; Le Fur G.; Pharmacological evidence of a possible tryptaminergic regulation of opiate receptors by using indalpine, a selective 5-HT uptake inhibitor. Neuropharmacology  1980,19(11),1075-1079","journal-title":"Neuropharmacology"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0022-3565(25)26715-5","volume":"143","author":"Harman R.E.","year":"1964","unstructured":"Harman R.E.; Meisinger M.A.P.; Davis G.E.; Kuehl F.A.; The metabolites of indomethacin, a new anti-inflammatory drug. J Pharmacol Exp Ther  1964,143(2),215-220","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0022-5347(01)63942-9","volume":"159","author":"Ernst E.","year":"1998","unstructured":"Ernst E.; Pittler M.H.; Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. J Urol  1998,159(2),433-436","journal-title":"J Urol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0163-7258(01)00156-5","volume":"91","author":"Tam S.W.","year":"2001","unstructured":"Tam S.W.; Worcel M.; Wyllie M.; Yohimbine: A clinical review. Pharmacol Ther  2001,91(3),215-243","journal-title":"Pharmacol Ther"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/head.12769","volume":"56","author":"Lucas S.","year":"2016","unstructured":"Lucas S.; The pharmacology of indomethacin. Headache  2016,56(2),436-446","journal-title":"Headache"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00003088-200241020-00003","volume":"41","author":"Dekhuijzen P.N.R.","year":"2002","unstructured":"Dekhuijzen P.N.R.; Koopmans P.P.; Pharmacokinetic profile of zafirlukast. Clin Pharmacokinet  2002,41(2),105-114","journal-title":"Clin Pharmacokinet"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00003495-199855010-00008","volume":"55","author":"Adkins J.C.","year":"1998","unstructured":"Adkins J.C.; Brogden R.N.; Zafirlukast. Drugs  1998,55(1),121-144","journal-title":"Drugs"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1016\/j.tet.2015.02.074","volume":"71","author":"Bennasar M.L.","year":"2015","unstructured":"Bennasar M.L.; Sol\u00e9 D.; Roca T.; Valldosera M.; Exploratory studies toward a total synthesis of pericine (subincanadine E). Tetrahedron  2015,71(15),2246-2254","journal-title":"Tetrahedron"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/BF01273159","volume":"103","author":"Maj J.","year":"1996","unstructured":"Maj J.; Kotodziejczyk K.; Rog\u00f3\u017c Z.; Skuza G.; Roxindole, a potential antidepressant I. Effect on the dopamine system. J Neural Transm (Vienna)  1996,103(5),627-641","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"101105","DOI":"10.1016\/j.rechem.2023.101105","volume":"6","author":"Sharma P.","year":"2023","unstructured":"Sharma P.; Thakur A.; Goyal A.; Singh Grewal A.; Molecular docking, 2D-QSAR and ADMET studies of 4-sulfonyl-2-pyridone heterocycle as a Potential glucokinase activator. Results Chem  2023,6,101105","journal-title":"Results Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2377-11-75","volume":"11","author":"Enciu A.M.","year":"2011","unstructured":"Enciu A.M.; Nicolescu M.I.; Manole C.G.; Mure\u015fanu D.F.; Popescu L.M.; Popescu B.O.; Neuroregeneration in neurodegenerative disorders. BMC Neurol  2011,11(1),75","journal-title":"BMC Neurol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40263-015-0249-8","volume":"29","author":"Robakis D.","year":"2015","unstructured":"Robakis D.; Fahn S.; Defining the role of the monoamine oxidaseb inhibitors for parkinson\u2019s disease. CNS Drugs  2015,29(6),433-441","journal-title":"CNS Drugs"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3389\/fphar.2016.00340","volume":"7","author":"Finberg J.P.M.","year":"2016","unstructured":"Finberg J.P.M.; Rabey J.M.; Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol  2016,7,340","journal-title":"Front Pharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"174S","DOI":"10.1592\/phco.27.12part2.174S","volume":"27","author":"Fernandez H.H.","year":"2007","unstructured":"Fernandez H.H.; Chen J.J.; Monoamine oxidase-B inhibition in the treatment of Parkinson\u2019s disease. Pharmacotherapy  2007,27(12P2),174S-185S","journal-title":"Pharmacotherapy"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.2174\/0115680266307132240509065351","volume":"24","author":"Rohilla S.","year":"2024","unstructured":"Rohilla S.; Goyal G.; Berwal P.; Mathur N.; A review on indole-triazole molecular hybrids as a leading edge in drug discovery: Current landscape and future perspectives. Curr Top Med Chem  2024,24(18),1557-1588","journal-title":"Curr Top Med Chem"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2174\/0118715273340983241018095529","volume":"24","author":"Rana N.","year":"2024","unstructured":"Rana N.; Grover P.; Parkinson\u2019s Disease: Unravelling the medicinal perspectives and recent developments of heterocyclic monoamine oxidase-B inhibitors. CNS Neurol Disord Drug Targets  2024,24(4),263-284","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"15196","DOI":"10.1038\/s41598-025-99534-3","volume":"15","author":"Chand J.","year":"2025","unstructured":"Chand J.; Jupudi S.; Ahmad S.F.; Emran T.B.; Subramanian G.; Therapeutic mechanistic study of novel indole derivatives as SIRTUIN3 modulators in Parkinson\u2019s disease with in vitro evaluation. Sci Rep  2025,15(1),15196","journal-title":"Sci Rep"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1021\/acschemneuro.4c00838","volume":"16","author":"Anastassova N.","year":"2025","unstructured":"Anastassova N.; Kondeva-Burdina M.; Hristova-Avakumova N.; Stefanova D.; Rangelov M.; Todorova N.; Yancheva D.; Exploring the Potential of Indole-3-acetic Acid Arylhydrazone Hybrids for Parkinson\u2019s Disease Treatment: A comprehensive evaluation of neuroprotective, MAOB inhibitory, and antioxidant properties. ACS Chem Neurosci  2025,16(6),1161-1181","journal-title":"ACS Chem Neurosci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.3390\/molecules29194770","volume":"29","author":"Mo X.","year":"2024","unstructured":"Mo X.; Rao D.P.; Kaur K.; Hassan R.; Abdel-Samea A.S.; Farhan S.M.; Br\u00e4se S.; Hashem H.; Indole Derivatives: A versatile scaffold in modern drug discovery\u2014an updated review on their multifaceted therapeutic applications (2020\u20132024). Molecules  2024,29(19),4770","journal-title":"Molecules"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1021\/acschemneuro.7b00050","volume":"8","author":"Nam M.H.","year":"2017","unstructured":"Nam M.H.; Park M.; Park H.; Kim Y.; Yoon S.; Sawant V.S.; Choi J.W.; Park J.H.; Park K.D.; Min S.J.; Lee C.J.; Choo H.; Indole-Substituted benzothiazoles and benzoxazoles as selective and reversible MAO-B inhibitors for treatment of Parkinson\u2019s disease. ACS Chem Neurosci  2017,8(7),1519-1529","journal-title":"ACS Chem Neurosci"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3988\/jcn.2005.1.1.81","volume":"1","author":"Han Y.S.","year":"2005","unstructured":"Han Y.S.; Kim J.M.; Cho J.S.; Lee C.S.; Kim D.E.; Comparison of the Protective Effect of Indole \u03b2-carbolines and R-(-)-deprenyl Against Nitrogen Species-Induced Cell Death in Experimental Culture Model of Parkinson\u2019s Disease. J Clin Neurol  2005,1(1),81-91","journal-title":"J Clin Neurol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1016\/j.ejmech.2010.07.005","volume":"45","author":"Prins L.H.A.","year":"2010","unstructured":"Prins L.H.A.; Petzer J.P.; Malan S.F.; Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem  2010,45(10),4458-4466","journal-title":"Eur J Med Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.bmcl.2016.03.060","volume":"26","author":"Chirkova Z.V.","year":"2016","unstructured":"Chirkova Z.V.; Kabanova M.V.; Filimonov S.I.; Abramov I.G.; Petzer A.; Petzer J.P.; Suponitsky K.Y.; An evaluation of synthetic indole derivatives as inhibitors of monoamine oxidase. Bioorg Med Chem Lett  2016,26(9),2214-2219","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.bmcl.2015.01.061","volume":"25","author":"Chirkova Z.V.","year":"2015","unstructured":"Chirkova Z.V.; Kabanova M.V.; Filimonov S.I.; Abramov I.G.; Petzer A.; Petzer J.P.; Firgang S.I.; Suponitsky K.Y.; Inhibition of monoamine oxidase by indole-5,6-dicarbonitrile derivatives. Bioorg Med Chem Lett  2015,25(6),1206-1211","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ardp.201600088","volume":"349","author":"Sasidharan R.","year":"2016","unstructured":"Sasidharan R.; Manju S.L.; U\u00e7ar G.; Baysal I.; Mathew B.; Identification of Indole\u2010Based Chalcones: Discovery of a Potent, Selective, and Reversible Class of MAO\u2010B Inhibitors. Arch Pharm  2016,349(8),627-637","journal-title":"Arch Pharm"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ddr.21425","volume":"79","author":"Chirkova Z.V.","year":"2018","unstructured":"Chirkova Z.V.; Kabanova M.V.; Filimonov S.I.; Abramov I.G.; Petzer A.; Engelbrecht I.; Petzer J.P.; Yu Suponitsky K.; Veselovsky A.V.; An investigation of the monoamine oxidase inhibition properties of pyrrolo[3,4\u2010 f]indole\u20105,7\u2010dione and indole\u20105,6\u2010dicarbonitrile derivatives. Drug Dev Res  2018,79(2),81-93","journal-title":"Drug Dev Res"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3390\/antiox10101641","volume":"10","author":"Elsherbeny M.H.","year":"2021","unstructured":"Elsherbeny M.H.; Kim J.; Gouda N.A.; Gotina L.; Cho J.; Pae A.N.; Lee K.; Park K.D.; Elkamhawy A.; Roh E.J.; Highly potent, selective, and competitive indole-based mao-b inhibitors protect PC12 cells against 6-hydroxydopamine- and rotenone-induced oxidative stress. Antioxidants  2021,10(10),1641","journal-title":"Antioxidants"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph17101292","volume":"17","author":"Vrban L.","year":"2024","unstructured":"Vrban L.; Vianello R.; Prominent neuroprotective potential of indole-2-N-methylpropargylamine: High affinity and irreversible inhibition efficiency towards monoamine oxidase b revealed by computational scaffold analysis. Pharmaceuticals  2024,17(10),1292","journal-title":"Pharmaceuticals"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.bioorg.2019.03.042","volume":"87","author":"Takao K.U.S.","year":"2019","unstructured":"Takao K.U.S.; Kamauchi H.; Sugita Y.; Design, synthesis and evaluation of 2-(indolylmethylidene)-2,3-dihydro-1-benzofuran-3-one and 2-(indolyl)-4H-chromen-4-one derivatives as novel monoamine oxidases inhibitors. Bioorg Chem  2019,87,594-600","journal-title":"Bioorg Chem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"7782","DOI":"10.1523\/JNEUROSCI.20-20-07782.2000","volume":"20","author":"Nash J.E.","year":"2000","unstructured":"Nash J.E.; Brotchie J.M.; A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J Neurosci  2000,20,7782-7789","journal-title":"J Neurosci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.baga.2013.09.001","volume":"3","author":"Carrillo-Mora P.","year":"2013","unstructured":"Carrillo-Mora P.; Silva-Adaya D.; Villase\u00f1or-Aguayo K.; Glutamate in Parkinson\u2019s disease: Role of antiglutamatergic drugs. Basal Ganglia  2013,3(3),147-157","journal-title":"Basal Ganglia"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/archneur.1991.00530210109030","volume":"48","author":"Greenamyre J.T.","year":"1991","unstructured":"Greenamyre J.T.; O\u2019Brien C.F.; N-methyl-D-aspartate antagonists in the treatment of Parkinson\u2019s disease. Arch Neurol  1991,48(9),977-981","journal-title":"Arch Neurol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","volume":"102","author":"Hallett P.J.","year":"2004","unstructured":"Hallett P.J.; Standaert D.G.; Rationale for and use of NMDA receptor antagonists in Parkinson\u2019s disease. Pharmacol Ther  2004,102(2),155-174","journal-title":"Pharmacol Ther"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1016\/j.bmc.2013.05.044","volume":"21","author":"Buemi M.R.","year":"2013","unstructured":"Buemi M.R.; De Luca L.; Chimirri A.; Ferro S.; Gitto R.; Alvarez-Builla J.; Alajarin R.; Indole derivatives as dual-effective agents for the treatment of neurodegenerative diseases: Synthesis, biological evaluation, and molecular modeling studies. Bioorg Med Chem  2013,21(15),4575-4580","journal-title":"Bioorg Med Chem"},{"key":"ref=112","author":"Upasani R.B.","year":"1999","unstructured":"Upasani R.B.; Keana J.F.W.; Department of Chemistry, University of Oregon,  1999"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.3390\/molecules29092127","volume":"29","author":"Barresi E.","year":"2024","unstructured":"Barresi E.; Baglini E.; Poggetti V.; Castagnoli J.; Giorgini D.; Salerno S.; Taliani S.; Da Settimo F.; Indole-Based compounds in the development of anti-Neurodegenerative agents. Molecules  2024,29(9),2127","journal-title":"Molecules"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.nbd.2018.01.004","volume":"112","author":"Mercado G.","year":"2018","unstructured":"Mercado G.; Castillo V.; Soto P.; L\u00f3pez N.; Axten J.M.; Sardi S.P.; Hoozemans J.J.M.; Hetz C.; Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson\u2019s disease. Neurobiol Dis  2018,112,136-148","journal-title":"Neurobiol Dis"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"107989","DOI":"10.1016\/j.neuropharm.2020.107989","volume":"167","author":"Kim S.","year":"2020","unstructured":"Kim S.; Indu Viswanath A.N.; Park J.H.; Lee H.E.; Park A.Y.; Choi J.W.; Kim H.J.; Londhe A.M.; Jang B.K.; Lee J.; Hwang H.; Lim S.M.; Pae A.N.; Park K.D.; Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson\u2019s disease animal model. Neuropharmacology  2020,167,107989","journal-title":"Neuropharmacology"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.expneurol.2017.05.009","volume":"295","author":"Moreira S.","year":"2017","unstructured":"Moreira S.; Fonseca I.; Nunes M.J.; Rosa A.; Lemos L.; Rodrigues E.; Carvalho A.N.; Outeiro T.F.; Rodrigues C.M.P.; Gama M.J.; Castro-Caldas M.; Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson\u2019s disease. Exp Neurol  2017,295,77-87","journal-title":"Exp Neurol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3390\/antiox11020247","volume":"11","author":"Duarte P.","year":"2022","unstructured":"Duarte P.; Michalska P.; Crisman E.; Cuadrado A.; Le\u00f3n R.; Novel Series of Dual NRF2 inducers and selective mao-b inhibitors for the treatment of parkinson\u2019s disease. Antioxidants  2022,11(2),247","journal-title":"Antioxidants"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"5074367","DOI":"10.1155\/2019\/5074367","volume":"2019","author":"Wei P.C.","year":"2019","unstructured":"Wei P.C.; Lee-Chen G.J.; Chen C.M.; Wu Y.R.; Chen Y.J.; Lin J.L.; Lo Y.S.; Yao C.F.; Chang K.H.; Neuroprotection of indole-derivative compound NC001-8 by the regulation of the NRF2 pathway in parkinson\u2019s disease cell models. Oxid Med Cell Longev  2019,2019,5074367","journal-title":"Oxid Med Cell Longev"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbi.2020.08.001","volume":"90","author":"Saini N.","year":"2020","unstructured":"Saini N.; Akhtar A.; Chauhan M.; Dhingra N.; Pilkhwal Sah S.; Protective effect of Indole-3-carbinol, an NF-\u03baB inhibitor in experimental paradigm of Parkinson\u2019s disease: In silico and in vivo studies. Brain Behav Immun  2020,90,108-137","journal-title":"Brain Behav Immun"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3233\/JPD-223179","volume":"12","author":"Chen S.J.","year":"2022","unstructured":"Chen S.J.; Chen C.C.; Liao H.Y.; Wu Y.W.; Liou J.M.; Wu M.S.; Kuo C.H.; Lin C.H.; Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson\u2019s Disease. J Parkinsons Dis  2022,12(4),1219-1230","journal-title":"J Parkinsons Dis"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/0006-8993(92)90576-U","volume":"570","author":"Collins M.A.","year":"1992","unstructured":"Collins M.A.; Neafsey E.J.; Matsubara K.; Cobuzzi R.J.; Rollema H.; Indole-N-methylated \u03b2-carbolinium ions as potential brain-bioactivated neurotoxins. Brain Res  1992,570(1-2),154-160","journal-title":"Brain Res"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"e0188212","DOI":"10.1371\/journal.pone.0188212","volume":"13","author":"Shao Y.M.","year":"2018","unstructured":"Shao Y.M.; Ma X.; Paira P.; Tan A.; Herr D.R.; Lim K.L.; Ng C.H.; Venkatesan G.; Klotz K.N.; Federico S.; Spalluto G.; Cheong S.L.; Chen Y.Z.; Pastorin G.; Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson\u2019s disease treatment. PLoS One  2018,13(1),e0188212","journal-title":"PLoS One"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s00044-016-1502-5","volume":"25","author":"Senthil Kumar J.B.","year":"2016","unstructured":"Senthil Kumar J.B.; Kumari R.; Luthra P.M.; Modulation of indole ring annulation in ergoline template: chemistry, receptor binding and in vivo pharmacology with 6-OHDA model of Parkinson\u2019s disease. Med Chem Res  2016,25(4),596-608","journal-title":"Med Chem Res"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.bbrc.2019.07.074","volume":"517","author":"Mimori S.","year":"2019","unstructured":"Mimori S.; Kawada K.; Saito R.; Takahashi M.; Mizoi K.; Okuma Y.; Hosokawa M.; Kanzaki T.; Indole-3-propionic acid has chemical chaperone activity and suppresses endoplasmic reticulum stress-induced neuronal cell death. Biochem Biophys Res Commun  2019,517(4),623-628","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1124\/jpet.112.201558","volume":"345","author":"De Miranda B.R.","year":"2013","unstructured":"De Miranda B.R.; Miller J.A.; Hansen R.J.; Lunghofer P.J.; Safe S.; Gustafson D.L.; Colagiovanni D.; Tjalkens R.B.; Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson\u2019s disease. J Pharmacol Exp Ther  2013,345(1),125-138","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"9142","DOI":"10.3390\/s23229142","volume":"23","author":"Palladino P.","year":"2023","unstructured":"Palladino P.; Rainetti A.; Lettieri M.; Pieraccini G.; Scarano S.; Minunni M.; Quantitative Colorimetric Sensing of Carbidopa in Anti-parkinson drugs based on selective reaction with indole-3-carbaldehyde. Sensors  2023,23(22),9142","journal-title":"Sensors"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575400809251007055201","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/246328\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575400809251007055201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T05:26:36Z","timestamp":1768541196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/246328\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":126,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113895575400809251007055201","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}